U.S. Professional Services Stock News

Wondering if Entergy at around US$110.48 is offering fair value right now, or if the recent run means you might be paying up for the stock. The stock has returned 1.7% over the past week, is down 2.2% over the past month, and sits on a 17.7% year to date gain, with 37.9% over 1 year, 141.7% over 3 years, and 145.7% over 5 years. Recent coverage has focused on Entergy as a regulated electric utility, with attention on its role in regional power infrastructure and ongoing investment needs...

On June 8, 2026, Brady Corporation announced that long‑time CEO Russell Shaller retired and was succeeded the same day by board member and former Allegro MicroSystems chief executive Vineet Nargolwala, who will guide the company as it integrates Honeywell’s Productivity Solutions and Services business. This leadership change places a veteran technology and Honeywell alumnus at the helm just as Brady undertakes one of its most complex acquisitions. We’ll now examine how appointing Vineet...

Caledonia Mining (NYSEAM:CMCL) has reported significant exploration results from its Motapa property in Zimbabwe, confirming substantial gold mineralisation across several zones. Motapa is located directly adjacent to the Bilboes Gold Project, pointing to possible extensions of existing mineralised structures and future operational synergies. A maiden resource estimate for Motapa is scheduled for Q3, which could be an important milestone for how investors assess the company’s gold resource...

CNX Resources (CNX) has drawn investor attention after a recent pullback, with the stock down about 8% over the past month and roughly 19% over the past 3 months. See our latest analysis for CNX Resources. That recent pullback sits within a mixed picture, with the share price down about 9% year to date and roughly 19% over 3 months, while the 1 year total shareholder return is 3.6% and the 3 and 5 year total shareholder returns are very strong. This suggests long term holders have still seen...

On June 1, 2026, O'Reilly Automotive increased its share repurchase authorization by an additional US$2.00 billion to a total of US$31.75 billion and extended the buyback program by three years. This enlarged, longer-duration buyback underscores management’s confidence in the company’s strong cash generation and high-return capital allocation, reinforcing its focus on shareholder returns. Next, we’ll examine how this expanded, longer-term buyback authorization might reshape O'Reilly...

Pinnacle West Capital recently completed a US$499.58 million fixed‑income offering of 4.650% senior unsecured notes due June 1, 2029, following the closure of a US$40.75 million dividend reinvestment common stock shelf and ahead of a special call held on June 8, 2026. Together, the sizable debt issuance, prior equity program completion, and subsequent special call highlight an active period of balance sheet planning that may shape how investors interpret the company’s capital plans and...

In recent months, Arbor Realty Trust has faced weaker net interest income growth, rising loan distress in its roughly US$12.00 billion portfolio, and a dividend cut following a soft first-quarter 2026 earnings report. Together with declining earnings per share, tangible book value per share, and earnings estimates, these developments highlight mounting profitability and credit pressures tied to tougher commercial real estate conditions. Next, we’ll examine how the elevated distress in...

Earlier this week, Lazard reported preliminary May 2026 assets under management of about US$284.8 billion, with US$11.6 billion of market appreciation offset by US$1.4 billion in client withdrawals and US$0.7 billion of currency depreciation. At the same time, recent insider share sales without any reported insider buying have raised fresh questions about how management views near-term business conditions. We’ll now examine how Lazard’s recent net outflows and currency headwinds may...

In early June 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and also received FDA approval, with 180 days of Competitive Generic Therapy exclusivity, for its romidepsin injection solution for cutaneous T-cell lymphoma. The CREXONT data highlighted meaningful gains in “Good On” time and motor control across prior treatment groups, while the romidepsin approval brought an oncology medicine back to the U.S. market in a...

Establishment Labs Holdings (ESTA) has drawn fresh attention after recent share price moves, with the stock up about 11% over the past month and roughly 25% in the past 3 months. See our latest analysis for Establishment Labs Holdings. The recent 7 day share price return of 9.74% and 90 day share price return of 24.95% come on top of a 1 year total shareholder return of 106.18%, pointing to momentum that has been building rather than fading. If you are comparing ESTA with other faster growing...

Recently, Zacks upgraded Brink's to a Rank #2 (Buy), citing a positive shift in analyst earnings estimates and a stronger earnings outlook for the company. This ratings change highlights how revisions to profit expectations can shape investor perception of Brink's evolving cash-management and digital services business model. Next, we'll examine how this more optimistic earnings outlook might influence Brink's broader investment narrative built around AMS and digital solutions. The future of...

Earlier this week, Vornado Realty Trust reported that PENN 2 in New York’s PENN DISTRICT is now 90% leased after signing 10–12 year full-floor agreements with technology tenants Veeva and Altana AI, which is establishing its new headquarters there. This leasing progress at a flagship redevelopment, coupled with increased interest across office REITs, highlights how high-quality, amenity-rich assets may be attracting tenants even as the broader office sector adjusts to new working...

On June 8, 2026, PTC Therapeutics announced that board member Alethia Young resigned to focus on other work commitments, while simultaneously entering a consulting agreement that keeps her advising the company through June 8, 2027. This move comes as PTC Therapeutics reports record revenue driven by strong global uptake of SEPHIENCE, underscoring the company’s emphasis on continuity of commercial and advisory expertise. We’ll now examine how record SEPHIENCE-driven revenue, alongside Alethia...

In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities. The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity. We’ll now examine how Maximus’ expanded term loan capacity and planned...

CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year. See our latest analysis for CG Oncology. Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very...

Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress. These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts. We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these...

In recent days, Clear Street analyst Tim Moore highlighted Willdan Group’s potential upside, citing expected revenue and adjusted EBITDA growth from power grid modernization and rising demand for energy-efficient and AI datacenter solutions, while company insiders sold about US$6.1 million of stock over the past three months. This combination of bullish analyst commentary on AI datacenter exposure and concurrent insider selling offers a contrasting signal about management’s and the market’s...

On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal. This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In this context of fluctuating market conditions, companies with high insider ownership and strong revenue growth potential can offer intriguing opportunities for investors seeking stability and alignment of interests between management and shareholders.

Over the last 7 days, the United States market has dropped 4.1%, but it remains up by 21% over the past year, with earnings expected to grow by 18% annually in the coming years. Investing in penny stocks—often smaller or newer companies—can still offer growth opportunities, especially when these stocks are backed by strong financial health. We'll explore several penny stocks that stand out for their financial strength and potential for long-term success.

Over the last 7 days, the United States market has dropped by 4.1%, though it has risen by an impressive 21% over the past year, with earnings forecasted to grow annually by 18%. In this dynamic environment, identifying dividend stocks that offer reliable income and potential for growth can be a prudent strategy for investors seeking stability amidst market fluctuations.

EHang Holdings Limited reported weaker Q1 2026 results on June 9, with CNY 25.66 million in sales and a CNY 125.96 million net loss, while reaffirming its 2026 revenue guidance of RMB 600 million. Alongside these results, the company authorized a new US$30 million share repurchase program funded from existing cash, signaling management’s confidence as it advances pilotless eVTOL commercialization. We’ll now examine how reaffirmed 2026 revenue guidance, despite soft Q1 sales, affects EHang’s...

With inflation pressures, energy shocks and rate expectations keeping markets on edge, many investors are looking for companies that already show high return on equity, sound past performance and robust balance sheets. Instead of chasing short term stories tied to every data release or central bank headline, this approach focuses on businesses that appear financially resilient and efficient. Using our Solid Balance Sheet and Fundamentals screener, this article highlights 3 stocks that...